Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2) - Maher, Toby M.; Kreuter, Michael; Lederer, David J.; Brown, Kevin K.; Wuyts, Wim; Verbruggen, Nadia; Stutvoet, Simone; Fieuw, Ann; Ford, Paul; Abi-Saab, Walid; Wijsenbeek, Marlies (BMJ Open Respiratory Research, 2019)
Gesehen am 13.10.2020